Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/167962SUBSTITUTED PYRAZOLYL COMPOUNDS AS MALT-1 INHIBITORS
WO 11.08.2022
Int.Class C07D 231/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
54condensed with carbocyclic rings or ring systems
Appl.No PCT/IB2022/050934 Applicant AURIGENE DISCOVERY TECHNOLOGIES LIMITED Inventor CHIKKANNA, Dinesh
The present invention is directed to compound of formula (I) and, a pharmaceutically acceptable salt or a stereoisomer thereof that useful as MALT-1 inhibitors for the treatment of diseases or disorders dependent on MALT-1. The present invention also relates to a method of preparation of the said compounds and pharmaceutical compositions comprising the said compounds.
2.WO/2022/166747AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO 11.08.2022
Int.Class C07D 207/277
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
273with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Appl.No PCT/CN2022/074272 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
The present invention relates to an amino lipid compound, namely a compound represented by chemical formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof. Moreover, also disclosed are a preparation method for the compound and a use of the compound in delivering a genetic material and preparing a drug.
3.WO/2022/166762CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO 11.08.2022
Int.Class C07D 491/147
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
147the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Appl.No PCT/CN2022/074328 Applicant SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Inventor TIAN, Qiang
The present invention relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as shown below or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound can be used as a drug for treating diseases in abnormal cell proliferation.
4.WO/2022/166792SALT, SOLVATE, POLYMORPH, PREPARATION METHOD AND USE OF BENZAZEPINE DERIVATIVE
WO 11.08.2022
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/CN2022/074486 Applicant SHANGHAI DE NOVO PHARMATECH CO., LTD. Inventor FU, Min
A salt, a solvate, a polymorph, a preparation method and the use of a benzazepine derivative. Specifically disclosed is a compound as shown in formula (I). The crystal form of the compound as shown in formula (I) has better solubility and stability, is more suitable for the preparation of a pharmaceutical dosage form, and the drug prepared from the compound as shown in formula (I) has better absorption and metabolic effects in the body.
5.WO/2022/1670021,4-SULFOBRIDGED POLYCYCLIC COMPOUND CONTAINING DIHYDROBENZOFURAN STRUCTURE, AND PREPARATION METHOD AND USE THEREFOR
WO 11.08.2022
Int.Class C07D 513/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/232
12in which the condensed system contains three hetero rings
18Bridged systems
Appl.No PCT/CN2022/081576 Applicant CHENGDU UNIVERSITY Inventor ZHAO, Jianqiang
Disclosed is a 1,4-sulfobridged polycyclic compound containing a dihydrobenzofuran structure, belonging to the field of organic synthesis, and having a structure as shown in formula (I). Further disclosed is a preparation method therefor comprising: dissolving 2-nitrobenzofuran (II) and 5H-thiazolinone (III) in an organic solvent, then adding a molecular sieve and a chiral catalyst, stirring to react at room temperature under the protection of argon, and after the reaction is completed, separating and purifying to obtain a 1,4-sulfobridged polycyclic compound containing a dihydrobenzofuran structure. The multi-ring compound provided by the present invention has a dihydrobenzofuran and a 1,4-sulfobridged piperidinone substructure. Also disclosed is a use of the compound in the preparation of an anti-tumor drug, and the compound has good potential value in anti-tumor drug research. The preparation method of the present invention has the advantages of novelty, simplicity, convenient operation, mild reaction conditions, high yield, high stereoselectivity, etc.
6.WO/2022/166642NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO 11.08.2022
Int.Class A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Appl.No PCT/CN2022/073467 Applicant APPLIED PHARMACEUTICAL SCIENCE, INC. Inventor ZHONG, Jun
A nitrogen-containing polycyclic fused ring compound represented by formula I, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. As a highly selective and effective RET inhibitor, the compound has a strong inhibitory effect on RET gatekeeper residue mutant RET V804M mutation, RET solvent front residue mutant G810R, and other clinically relevant RET mutants and RET-wt. The compound can also significantly inhibit the growth of a TT cell line derived from thyroid cancer and Ba/F3 cells transformed by various RET mutants, and has a stronger inhibition effect than selective RET inhibitor LOXO-292. In addition, the compound can greatly block cellular RET autophosphorylation and downstream pathways, and can significantly induce TT cell death.
7.WO/2022/165607HIGH LOADING ORAL FILM FORMULATION
WO 11.08.2022
Int.Class A61K 9/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
70Web, sheet or filament bases
Appl.No PCT/CA2022/050171 Applicant INTELGENX CORP. Inventor TIR, Billal
An oral film dosage form with high loading of active pharmaceutical ingredients, comprising a suspending agent/viscosity increasing agent, a mucoadhesive film former, an amphiphilic solubility enhancer, a non-amphipathic solubility enhancer, an agglomeration inhibitor, and a surfactant. The oral film dosage form comprises at least 40mg active pharmaceutical ingredient, representing 22% of the dry weight of the oral film. Also disclosed are oral films comprising a low-solubility active pharmaceutical ingredient at an acidic pH.
8.WO/2022/169747METHOD FOR PREPARING LEVETIRACETAM AND INTERMEDIATES THEREOF
WO 11.08.2022
Int.Class C07D 207/27
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
263with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
27with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Appl.No PCT/US2022/014698 Applicant VITAWORKS IP, LLC Inventor HU, Songzhou
There is disclosed a method for preparing levetiracetam and intermediates from a compound of the formula: (I) wherein CR is selected from the group consisting of cyano, carboxylic acid, carboxamide, alkali carboxyl ate, alkaline earth metal carboxyl ate, alkyl carboxyl ate, and a mixture thereof.
9.WO/2022/169897CRYSTALLINE FORMS OF A CYCLIN-DEPENDENT KINASE INHIBITOR
WO 11.08.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2022/014974 Applicant NUVATION BIO INC. Inventor BIGERT, Matthew John
Provided herein are crystalline forms of a cyclin-dependent kinases (CDK) inhibitor, compositions thereof, methods of preparation thereof, and methods of use thereof.
10.WO/2022/170122QUINOXALINE DERIVATIVES AND USES THEREOF
WO 11.08.2022
Int.Class C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
Appl.No PCT/US2022/015353 Applicant BLACK DIAMOND THERAPEUTICS, INC. Inventor LUCAS, Matthew C.
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.